Skip to content

Clinical efficacy and safety of clofibroxaol in the treatment of non-thrombolytic cerebral infarction and transient ischemic attack: a real-world retrospective study based on case database

Clinical efficacy and safety of clofibroxaol in the treatment of non-thrombolytic cerebral infarction and transient ischemic attack: a real-world retrospective study based on case database

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900025936
Enrollment
Unknown
Registered
2019-09-15
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute ischemic stroke

Interventions

Control group:Aspirin and/or Clopidogrel

Sponsors

The Affiliated Weihai Central Hospital of Qingdao University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Age >=18 years old; 2) The time from onset or waking stroke (from the onset of sleep to the onset time) to the time of treatment within 48 hours; 3) Diagnosis of acute cerebral infarction or transient ischemic attack based on clinical symptoms or head CT or MRI assessment; 4) According to the clinical signs and symptoms at the time of onset, the NIHSS score is <=15 points; 5) receiving treatment with tirofiban or aspirin or clopidogrel.

Exclusion criteria

Exclusion criteria: 1) Confirmation of intracranial hemorrhage by head CT or MRI; 2) mRS score >=2 points before onset; 3) pregnant or lactating women; 4) Allergic to tirofiban and contrast agents; 5) combined with severe infection or cardiopulmonary insufficiency; 6) blood glucose 22.2mmol/L (400mg / dl), platelets 200mmol/L (2.5mg/dl); 9) The life expectancy of any disease is <6 months in the late stage; 10) Imaging exists brain tumors with a placeholder effect.

Design outcomes

Primary

MeasureTime frame
90d mRS score;Incidence of symptomatic intracranial hemorrhage within 48 hours;90 d mortality;

Secondary

MeasureTime frame
90 d mRS score 0-2 points (%);The NIHSS score changed 24 h after treatment;;The NIHSS score changed 7 d after treatment;;The incidence of asymptomatic intracranial hemorrhage within 48h;The incidence of non-intracranial hemorrhage within 7 days;thrombocytopenia within 7d;

Countries

China

Contacts

Public ContactYongpeng Yu

The Affiliated Weihai Central Hospital of Qingdao University

yypeng6688@126.com+86 15192808182

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026